Sanofi invests billions into Frankfurt insulin production site
![](/46/pdcnewsitem/12/50/35/Heading%20image%20(20).png)
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production.
The expansion will include an additional 36,000 square metres to the existing facility and is expected to be operational by 2029. The project is partly support by the German national government and the government of the regional state of Hesse pending EU approval. As one of the leading global producers of insulin, the German government hopes this investment will bolster pharmaceutical R&D in the country, priming the nation as a leading pharmaceutical hub.
“The Sanofi expansion is great news for Germany as a pharmaceuticals location and an expression of Germany’s past and future strength in the area,” commented Robert Hermann, Germany Trade & Invest CEO. “The German government sees pharma as an economic pillar in the years to come, and the incentives and reforms it has promoted are encouraging some of the biggest names in the global industry to put their faith in the country.”
The German national government officially adopted a pharmaceutical strategy in 2023 intended to bolster support for global companies to streamline approval and improve R&D conditions in Germany. This strategy has attracted the likes of Eli Lilly, Daiichi-Sankyo, and Roche into investing in their own billion-euro ventures in the country. “There’s every reason to expect that more and more international companies will follow suit,” stated Hermann.
“With this project, we reaffirm our commitment to help diabetes sufferers around the world,” said Brendan O’Callaghan, Global Head of Manufacturing & Supply at Sanofi. “We’re using the long-time expertise of our Frankfurt BioCampus and its highly qualified personnel.”
Heidrun Irschik-Hadjieff, chairman of Sanofi in Germany, added “Our planned investment underscores the central role played by the Frankfurt BioCampus in strengthening the resilience of global insulin production. The strong support of both the national and regional German governments is a powerful signal for the biopharmaceutical industry.”
Source:
Germany attracts another billion-euro pharma project [Accessed August 2, 2024] https://www.prnewswire.com/news-releases/germany-attracts-another-billion-euro-pharma-project-302212375.html
Related News
-
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Alzheimer’s drug Leqembi rejected by EU drug regulator
The European Medicine’s Agency (EMA), the drug regulator for the EU, rejected Eisai and Biogen’s Alzheimer’s drug product Leqembi, citing the drug’s slowing of cognitive decline did not outweigh the risk of serious brain swellin... -
News Second obesity drug candidate from Roche shows early trial success
Following from its purchase of Carmot Therapeutics, Roche have announced positive early-stage trial success for its second obesity drug candidate acquired from Carmot Therapeutics. -
News Tumour microproteins could provide basis for cancer vaccines
A recent study published in Science Advances has identified a set of microproteins produced exclusively in liver tumours, which may provide a clear target for the development of a cancer vaccine. -
News Reworked once-daily weight-loss pill from Pfizer to progress
American pharmaceutical giant Pfizer have continued with a reworked version of their weight-loss pill danuglipron, progressing with a once-daily version of the pill. -
News CPHI Online Trend Report: what is pharmaceutical packaging really costing the industry?
The latest CPHI Online Trend Report dives into what it really costs to develop, manufacture, and deploy pharmaceutical packaging that balances sustainability concerns, patient safety, and drug efficacy. -
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance